Oppenheimer & Co. Inc. Sells 3,000 Shares of Genomic Health Inc. (GHDX)
Oppenheimer & Co. Inc. lowered its stake in Genomic Health Inc. (NASDAQ:GHDX) by 2.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,749 shares of the company’s stock after selling 3,000 shares during the period. Oppenheimer & Co. Inc. owned approximately 0.42% of Genomic Health worth $4,013,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in GHDX. Bank of Montreal Can purchased a new stake in shares of Genomic Health during the second quarter worth approximately $187,000. Stonebridge Capital Management Inc. purchased a new stake in shares of Genomic Health during the third quarter worth approximately $223,000. AQR Capital Management LLC purchased a new stake in shares of Genomic Health during the second quarter worth approximately $270,000. American International Group Inc. increased its stake in shares of Genomic Health by 3.2% in the second quarter. American International Group Inc. now owns 10,753 shares of the company’s stock worth $278,000 after buying an additional 334 shares in the last quarter. Finally, Nationwide Fund Advisors increased its stake in shares of Genomic Health by 3.0% in the second quarter. Nationwide Fund Advisors now owns 11,932 shares of the company’s stock worth $309,000 after buying an additional 351 shares in the last quarter. 89.65% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Genomic Health Inc. (NASDAQ:GHDX) traded up 0.81% during mid-day trading on Tuesday, reaching $31.16. 109,940 shares of the company were exchanged. Genomic Health Inc. has a 12 month low of $22.00 and a 12 month high of $35.79. The firm’s market capitalization is $1.04 billion. The company’s 50-day moving average is $30.58 and its 200 day moving average is $28.22.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, November 1st. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $82.30 million for the quarter, compared to analysts’ expectations of $83.24 million. Genomic Health had a negative net margin of 5.77% and a negative return on equity of 14.13%. Genomic Health’s revenue was up 11.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.36) earnings per share. Analysts predict that Genomic Health Inc. will post ($0.46) EPS for the current year.
A number of brokerages have commented on GHDX. Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, August 4th. Canaccord Genuity restated a “buy” rating and issued a $38.00 target price on shares of Genomic Health in a report on Friday, August 5th. Jefferies Group upped their target price on shares of Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, August 17th. Finally, Bank of America Corp. set a $28.00 target price on shares of Genomic Health and gave the company a “sell” rating in a report on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $32.50.
In other Genomic Health news, insider James J. Vaughn sold 3,000 shares of Genomic Health stock in a transaction that occurred on Thursday, October 6th. The shares were sold at an average price of $29.68, for a total transaction of $89,040.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Steven Shak sold 5,000 shares of Genomic Health stock in a transaction that occurred on Tuesday, September 13th. The shares were sold at an average price of $26.83, for a total transaction of $134,150.00. Following the transaction, the insider now directly owns 332,207 shares in the company, valued at $8,913,113.81. The disclosure for this sale can be found here. Company insiders own 47.00% of the company’s stock.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.